SCHEMBL2202133

SCHEMBL2202133

O=C1Nc2ccc(F)cc2C1=C1OCc2nc(CCCN3CCCC(O)C3)ccc21

nearest known ligand 0.38

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 12/20 0.38
KDR P35968 12/20 0.38
KIT P10721 7/20 0.38
FGFR1 P11362 1/20 0.34
TLK2 Q86UE8 1/20 0.34
LRRK2 Q5S007 2/20 0.34
FLT3 P36888 3/20 0.34
TOP1 P11387 2/20 0.34
CSF1R P07333 1/20 0.34
PDGFRA P16234 1/20 0.34
FLT1 P17948 1/20 0.34
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2202130 1.00 PDGFRB (0.38) PDGFRBKDRKITFGFR1TLK2
SCHEMBL12225685 1.00 PDGFRB (0.38) PDGFRBKDRKITFGFR1TLK2
SCHEMBL12431854 0.95 PDGFRB (0.38) PDGFRBKDRKITFGFR1TLK2
SCHEMBL2198534 0.95 PDGFRB (0.38) PDGFRBKDRKITFGFR1TLK2
SCHEMBL2198535 0.95 PDGFRB (0.38) PDGFRBKDRKITFGFR1TLK2
SCHEMBL12225659 0.90 PDGFRB (0.39) PDGFRBKDRKITFGFR1TLK2
SCHEMBL2202918 0.90 PDGFRB (0.38) PDGFRBKDRKITFGFR1TLK2
SCHEMBL2199895 0.90 PDGFRB (0.39) PDGFRBKDRKITFGFR1TLK2
SCHEMBL12225682 0.90 PDGFRB (0.38) PDGFRBKDRKITFGFR1TLK2
SCHEMBL2199892 0.90 PDGFRB (0.39) PDGFRBKDRKITFGFR1TLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977351-B2 Heteroaryl dihydroindolones as kinase inhibitors ALLERGAN, INC. (US) 2011-07-12 US claimed
US-20080045526-A1 HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS ALLERGAN, INC. 2008-02-21 US claimed
WO-2007109596-A2 HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2007-09-27 WO claimed
US-8455535-B2 Heteroaryl dihydroindolones as kinase inhibitors ALLERGAN, INC. (US) 2013-06-04 US disclosed
US-20110257238-A1 Heteroaryl Dihydroindolones as Kinase Inhibitors ALLERGAN, INC. (US) 2011-10-20 US disclosed
US-7977351-B2 Heteroaryl dihydroindolones as kinase inhibitors ALLERGAN, INC. (US) 2011-07-12 US disclosed
US-20080045526-A1 HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS ALLERGAN, INC. 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257238-A1 Heteroaryl Dihydroindolones as Kinase Inhibitors REN, JAK2, ABL1 PDGFRB 11/4885KDR 25/4885KIT 367/4885
US-20080045526-A1 HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS REN, JAK2, ABL1 PDGFRB 11/4885KDR 25/4885KIT 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.